Stockscreener 앱 받기
1.39
0.71%
-0.01
시간 외 거래:
1.40
0.01
+0.72%
전일 마감가:
$1.40
열려 있는:
$1.4
하루 거래량:
266.82K
Relative Volume:
0.40
시가총액:
$84.55M
수익:
-
순이익/손실:
$-24.25M
주가수익비율:
-2.0453
EPS:
-0.6796
순현금흐름:
$-19.95M
1주 성능:
-1.42%
1개월 성능:
+6.92%
6개월 성능:
-29.44%
1년 성능:
-12.03%
1일 변동 폭
$1.35
$1.40
1주일 범위
$1.335
$1.41
52주 변동 폭
$0.87
$3.19
MAIA Biotechnology Inc Stock (MAIA) Company Profile
명칭
MAIA Biotechnology Inc
전화
312 416 8592
주소
444 West Lake Street, Suite 1700, Chicago
Compare MAIA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.39 | 85.16M | 0 | -24.25M | -19.95M | -0.6796 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
MAIA Biotechnology Inc 주식(MAIA)의 최신 뉴스
Centric Wealth Management Takes Position in MAIA Biotechnology, Inc. $MAIA - MarketBeat
Solas Capital discloses 4.9% MAIA Biotechnology (MAIA) stake in Schedule 13G/A - Stock Titan
Maia Biotechnology Inc (MAIA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MAIA Biotechnology Q2 Results: EPS misses estimates - scanx.trade
MAIA Biotechnology 6M 2026: Net loss $(14.31M), Diluted EPS $(0.27) — 10-Q Summary - TradingView
MAIA Biotechnology (MAIA) Projected to Release Earnings on Monday - MarketBeat
MAIA Biotechnology Q1 2026 Earnings: EPS Beats Estimates, No Revenue ReportedEarnings Beat Alert - dars.gov.et
MAIA Biotechnology, Inc. Revenue Breakdown – AMEX:MAIA - TradingView
MAIA|Maia Biotechnology Inc|Price:1.255|Chg%:+0.005 - TradingKey
Maia Biotechnology Inc (MAIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Maia Biotechnology Inc (MAIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maia Biotechnology Inc (MAIA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maia Biotechnology Inc (MAIA) Institutional Confidence - TradingKey
MAIA|Maia Biotechnology Inc|Price:1.240|Chg%:-0.040 - TradingKey
Maia Biotechnology Inc (MAIA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maia Biotechnology Inc (MAIA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Maia Biotechnology Inc (MAIA) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Maia Biotechnology Inc (MAIA) Valuation: PE, PB & Fair Value Analysis - TradingKey
MAIA|Maia Biotechnology Inc|Price:1.290|Chg%:+0.050 - TradingKey
Maia Biotechnology Inc (MAIA) Cash Flow - TradingKey
MAIA Biotechnology Edges Lower as Support Level Faces TestVol Target Rebalance - Bölüm Sonu Canavarı
Noble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA) - The Globe and Mail
Data released by MAIA Biotechnology Inc. show that the combination therapy of its candidate drug Apatganosin with Ximiprilizumab demonstrated an acceptable safety profile in a heavily pre-treated population of patients with advanced solid tumors. - Bitget
Maia Biotechnology Reports Initial Efficacy Data from Phase 2 Thio-101 Part C Expansion Trial in Third-Line Non-Small Cell Lung Cancer - marketscreener.com
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial - The Manila Times
MAIA Biotechnology Reports 90.5% Interim Disease Control Rate in Phase 2 THIO-101 Part C for Advanced NSCLC - Quiver Quantitative
MAIA Biotechnology Reports Strong Initial Efficacy Data in - GlobeNewswire
MAIA Biotechnology (MAIA) Faces Selling Pressure as Shares Approach Key SupportIPO Entry Watch - dars.gov.et
MAIA Biotechnology Inc. (MAIA) Rises 3.1% as Shares Approach Key ResistanceVolume Profile - DonanımHaber
Enterprise value to EBITDA forward of MAIA Biotechnology, Inc. – AMEX:MAIA - TradingView
Price to earnings forward of MAIA Biotechnology, Inc. – BOATS:MAIA - TradingView
MAIAMAIA Biotechnology Inc Dividends - Finviz
ETFs Investing in MAIA Biotechnology, Inc. Stocks - TradingView
MAIA Biotechnology (MAIA) director receives grant of 26,982 stock options - Stock Titan
MAIA Biotechnology (MAIA) director awarded 26,355 stock options at $1.44 - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) director receives 32,630 stock options grant - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) director granted 27,610 stock options at $1.44 strike - Stock Titan
Director at MAIA Biotechnology (MAIA) receives 32,003 stock options grant - Stock Titan
26,355 stock options granted to MAIA (NASDAQ: MAIA) director Jean-Manasse - Stock Titan
MAIA Q1 2026 Earnings: Narrower Loss Beats Expectations as Clinical Pipeline AdvancesRevenue Report - dars.gov.et
MAIA Forecast — Price Target — Prediction for 2027 - TradingView
MAIA Biotechnology, Inc. Actuals & Estimates (AMEX:MAIA) - TradingView
MAIA Biotechnology, Inc. Actuals & Estimates (BOATS:MAIA) - TradingView
Why Is MAIA Biotechnology (NYSE:MAIA) Tracking Higher on Trial News? - Kalkine Media
MAIA finishes THIO-101 enrollment abroad, with 41 lung cancer patients treated - Stock Titan
Why Gold Prices Are CrashingACT NOW! Vincenzo Italiano (pm3QIbzhx7) - Fathom Journal
MAIA Biotechnology completes global enrollment in Phase 2 THIO-101 trial - scanx.trade
MAIA Biotechnology (MAIA) Edges Higher Amid Biotech Sector Interest — Key Levels in FocusCTA Positioning - dars.gov.et
Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
MAIA Should I Buy - Intellectia AI
MAIA Gains on Setting up New Site - Baystreet.ca
MAIA Biotechnology Inc (MAIA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
1.77%
자본화:
|
볼륨(24시간):